Alzamend Neuro is trading 5.9% down today at $1.12 amid broader biotech sector weakness and risk-off sentiment tied to escalating U.S.–Iran geopolitical tensions.
- There are no fresh company-specific headlines, SEC filings, or analyst calls today to account for the price action.
- The move appears to be driven by sector-wide and macro-economic pressures rather than changes to the company's fundamental outlook.